Loading clinical trials...
Loading clinical trials...
Compare the Safety and Efficacy of 177Lu-DOTATATE and Octreotide LAR in Unresectable or Metastatic, Progressive, Well-differentiated(G1 and G2) and SSTR-positive Adult GEP-NEN
Conditions
Interventions
177Lu-DOTATATE injection
Octreotide LAR (Long-acting release)
Locations
1
China
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Start Date
December 12, 2023
Primary Completion Date
November 24, 2026
Completion Date
February 24, 2027
Last Updated
July 10, 2025
Lead Sponsor
HTA Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions